Pharma · Private company
Merck KGaA, Darmstadt, Germany
Track this companyFree. Adds Merck KGaA, Darmstadt, Germany to your Dealase workspace and tells you when its record changes.
Clinical trials2517 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials25
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]PHASE3 · RECRUITING · started Oct 22, 2026ClinicalTrials.gov NCT07840287 · fetched Nov 12, 2026
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)PHASE3 · RECRUITING · started May 6, 2026ClinicalTrials.gov NCT07549412 · fetched Nov 12, 2026
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)PHASE3 · RECRUITING · started Apr 1, 2026ClinicalTrials.gov NCT07355218 · fetched Nov 12, 2026
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseasePHASE3 · RECRUITING · started Mar 10, 2026ClinicalTrials.gov NCT07332481 · fetched Nov 12, 2026
- Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsPHASE1 · RECRUITING · started Feb 13, 2026ClinicalTrials.gov NCT07360314 · fetched Nov 12, 2026
- M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsPHASE1 · RECRUITING · started Oct 10, 2025ClinicalTrials.gov NCT07166601 · fetched Nov 12, 2026
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 29, 2025ClinicalTrials.gov NCT06710132 · fetched Nov 12, 2026
- Anti-GD2 ADC M3554 in Advanced Solid TumorsPHASE1 · RECRUITING · started Nov 8, 2024ClinicalTrials.gov NCT06641908 · fetched Nov 12, 2026
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)PHASE2 · COMPLETED · started Oct 30, 2024ClinicalTrials.gov NCT06433219 · fetched Nov 12, 2026
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)PHASE1 · ACTIVE_NOT_RECRUITING · started Aug 7, 2024ClinicalTrials.gov NCT06421935 · fetched Nov 12, 2026
- Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)PHASE1_PHASE2 · COMPLETED · started Sep 13, 2023ClinicalTrials.gov NCT05882734 · fetched Nov 12, 2026
- Study of M5049 in DM and PM Participants (NEPTUNIA)PHASE2 · TERMINATED · started Jan 19, 2023ClinicalTrials.gov NCT05650567 · fetched Nov 12, 2026
- Met Non Small Cell Cancer Registry (MOMENT)RECRUITING · started Oct 4, 2022ClinicalTrials.gov NCT05376891 · fetched Nov 12, 2026
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)PHASE1 · ACTIVE_NOT_RECRUITING · started Aug 4, 2022ClinicalTrials.gov NCT05464030 · fetched Nov 12, 2026
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 11, 2022ClinicalTrials.gov NCT05217446 · fetched Nov 12, 2026
- Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)PHASE1 · COMPLETED · started Jun 7, 2022ClinicalTrials.gov NCT05396833 · fetched Nov 12, 2026
- A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 21, 2020ClinicalTrials.gov NCT04607421 · fetched Nov 12, 2026
- First in Human Study of M6223PHASE1 · COMPLETED · started Jul 10, 2020ClinicalTrials.gov NCT04457778 · fetched Nov 12, 2026
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)PHASE1 · COMPLETED · started Dec 20, 2019ClinicalTrials.gov NCT04170153 · fetched Nov 12, 2026
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)PHASE2 · COMPLETED · started Sep 19, 2019ClinicalTrials.gov NCT03940703 · fetched Nov 12, 2026
- Avelumab Program Rollover StudyPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 22, 2019ClinicalTrials.gov NCT03815643 · fetched Nov 12, 2026
- Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerPHASE2 · COMPLETED · started Jan 17, 2019ClinicalTrials.gov NCT03693170 · fetched Nov 12, 2026
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 13, 2018ClinicalTrials.gov NCT03547973 · fetched Nov 12, 2026
- Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 1, 2017ClinicalTrials.gov NCT03260023 · fetched Nov 12, 2026
- Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 13, 2016ClinicalTrials.gov NCT02864992 · fetched Nov 12, 2026